Derangement of immune responses by myeloid suppressor cells - PubMed (original) (raw)

Review

Derangement of immune responses by myeloid suppressor cells

Paolo Serafini et al. Cancer Immunol Immunother. 2004 Feb.

Abstract

In tumor-bearing mice and cancer patients, tumor progression is often associated with altered hematopoiesis leading to the accumulation of myeloid cells. Extensive studies in preclinical models indicate that these cells share the CD11b and the Gr-1 markers, possess a mixed mature-immature myeloid phenotype, and are responsible for the induction of T-cell dysfunctions, both tumor-specific and nonspecific. Moreover, CD11b(+)Gr-1(+) myeloid cells are described under different unrelated situations associated with temporary impairment of the T-lymphocyte reactivity. This review examines recent findings on the nature, properties, and mechanisms of action of these myeloid suppressor cells (MSCs).

PubMed Disclaimer

Similar articles

• Tumor-induced immune dysfunctions caused by myeloid suppressor cells.
  Bronte V, Serafini P, Apolloni E, Zanovello P. Bronte V, et al. J Immunother. 2001 Nov-Dec;24(6):431-46. doi: 10.1097/00002371-200111000-00001. J Immunother. 2001. PMID: 11759067 Review.
• Immature myeloid cells and cancer-associated immune suppression.
  Kusmartsev S, Gabrilovich DI. Kusmartsev S, et al. Cancer Immunol Immunother. 2002 Aug;51(6):293-8. doi: 10.1007/s00262-002-0280-8. Epub 2002 Apr 24. Cancer Immunol Immunother. 2002. PMID: 12111117 Free PMC article. Review.
• Myeloid-derived suppressor cell heterogeneity and subset definition.
  Peranzoni E, Zilio S, Marigo I, Dolcetti L, Zanovello P, Mandruzzato S, Bronte V. Peranzoni E, et al. Curr Opin Immunol. 2010 Apr;22(2):238-44. doi: 10.1016/j.coi.2010.01.021. Epub 2010 Feb 17. Curr Opin Immunol. 2010. PMID: 20171075 Review.
• Antigen specificity of immune suppression by myeloid-derived suppressor cells.
  Solito S, Bronte V, Mandruzzato S. Solito S, et al. J Leukoc Biol. 2011 Jul;90(1):31-6. doi: 10.1189/jlb.0111021. Epub 2011 Apr 12. J Leukoc Biol. 2011. PMID: 21486906 Review.
• CD80 in immune suppression by mouse ovarian carcinoma-associated Gr-1+CD11b+ myeloid cells.
  Yang R, Cai Z, Zhang Y, Yutzy WH 4th, Roby KF, Roden RB. Yang R, et al. Cancer Res. 2006 Jul 1;66(13):6807-15. doi: 10.1158/0008-5472.CAN-05-3755. Cancer Res. 2006. PMID: 16818658

Cited by

• Protein Tyrosine Phosphatase CD45 As an Immunity Regulator and a Potential Effector of CAR-T therapy.
  Volkov DV, Stepanova VM, Rubtsov YP, Stepanov AV, Gabibov AG. Volkov DV, et al. Acta Naturae. 2023 Jul-Sep;15(3):17-26. doi: 10.32607/actanaturae.25438. Acta Naturae. 2023. PMID: 37908772 Free PMC article.
• TIMM8A is associated with dysfunction of immune cell in BRCA and UCEC for predicting anti-PD-L1 therapy efficacy.
  Zhu X, Yuan Z, Cheng S, Wang H, Liao Y, Zhou D, Wu Z. Zhu X, et al. World J Surg Oncol. 2022 Oct 7;20(1):336. doi: 10.1186/s12957-022-02736-6. World J Surg Oncol. 2022. PMID: 36207751 Free PMC article.
• The antitumor activity of hPRDX5 against pancreatic cancer and the possible mechanisms.
  Cui L, Jin Y, Zou S, Xun J, Yu X, Zhang Q, Yang Z. Cui L, et al. Braz J Med Biol Res. 2022 Sep 12;55:e12324. doi: 10.1590/1414-431X2022e12324. eCollection 2022. Braz J Med Biol Res. 2022. PMID: 36102418 Free PMC article.
• DAT and TH expression marks human Parkinson's disease in peripheral immune cells.
  Gopinath A, Mackie P, Hashimi B, Buchanan AM, Smith AR, Bouchard R, Shaw G, Badov M, Saadatpour L, Gittis A, Ramirez-Zamora A, Okun MS, Streit WJ, Hashemi P, Khoshbouei H. Gopinath A, et al. NPJ Parkinsons Dis. 2022 Jun 7;8(1):72. doi: 10.1038/s41531-022-00333-8. NPJ Parkinsons Dis. 2022. PMID: 35672374 Free PMC article.
• Cancer Immunoediting: Elimination, Equilibrium, and Immune Escape in Solid Tumors.
  Wilczyński JR, Nowak M. Wilczyński JR, et al. Exp Suppl. 2022;113:1-57. doi: 10.1007/978-3-030-91311-3_1. Exp Suppl. 2022. PMID: 35165859

References

1. 1. Ahlers Proc Natl Acad Sci U S A. 2002;99:13020. - PubMed
2. 1. al Microb Pathog. 1992;12:267. - PubMed
3. 1. Albina J Surg Res. 1993;55:97. - PubMed
4. 1. Almand Clin Cancer Res. 2000;6:1755. - PubMed
5. 1. Almand J Immunol. 2001;166:678. - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Europe PubMed Central
  • PubMed Central
  • Springer

• Other Literature Sources

  • The Lens - Patent Citations Database

• Research Materials

  • NCI CPTC Antibody Characterization Program